Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Yes, B has been studies as anti-infective in eye. Conclusions so far:

At this point, BRI 0.5% appears to be a narrow-spectrum staphylococcal anti-infective. There appears to be no distinction between MSSA and MRSA. Additional rabbit keratitis testing of Streptococcus species and Gram-negatives (i.e., P. aeruginosa) needs to be evaluated to extend BRI 0.5% as a broad-spectrum anti-infective. The treatment indications, based on the current study, could support clinical trials for keratitis and conjunctivitis. The poor penetration of BRI 0.5% through the corneal epithelium probably would render the anti-infective as an inadequate choice for surgical prophylaxis.

In summary, BRI 0.5% is a narrow-spectrum anti-infective that is minimally irritating and appears to penetrate the corneal epithelium poorly. Testing should be extended to determine anti-infective concentration in the ocular tissues for the treatment of streptococcal and Gram-negative bacteria. Our laboratory is independent in any recommendation for the future development of BRI.

You will find more details here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742993/